The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“ing anti-Aß monoclonal antibodies including lecanemab [9], gantenerumab [10], and donanemab [11] and the many”
BackgroundSelf-citationSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Self-citationStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 369
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 252
Self-citationAlexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
IMMEDIATE CARE OF ACUTE BLUNT LARYNGEAL TRAUMA
Nahum, A. M. (1969) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-196902000-00003 · Cited by 57
Sabbagh, M. N., & Cummings, J. L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12235 · Cited by 47
Self-citation
Research works printed but not linked: 2
- Haeberlein SB, von Hehn C, Tian Y, et al., editors. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. San Diego, CA: 12th Clinical Trials on Alzheimer's Disease; 2019.
- Food and Drug Administration, Center for Drug Evaluation and Research. Formal meetings between the FDA and sponsors or applicants of PDUFA Products Guidance for Industry. Silver Spring, MD: Office of Communictions, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration; 2017.
Cited by
Sorted by citations
Items 101–200 of 223
Saunders, S., Ritchie, C. W., Russ, T. C., Terrera, G. M., & Milne, R. (2022) · BMC Geriatrics · doi:10.1186/s12877-021-02693-x · Cited by 16
Cuberas‐Borrós, G., Roca, I., Castell‐Conesa, J., Núñez, L., Boada, M., López, O. L., Grifols, C., Barceló, M., Pareto, D., & Páez, A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05915-5 · Cited by 14
Spatial extent as a sensitive amyloid‐PET metric in preclinical Alzheimer's disease
Farrell, M. E., Thibault, E. G., Becker, J. A., Price, J. C., Healy, B. C., Hanseeuw, B. J., Buckley, R. F., Jacobs, H. I. L., Schultz, A. P., Chen, C. D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14036 · Cited by 13
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 14
Lam, V., Clarnette, R., Francis, R. J., Bynevelt, M., Watts, G. F., Flicker, L. A., Orr, C., Loh, P. S., Lautenschlager, N. T., Reid, C. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058826 · Cited by 13
Taylor, H. A., Simmons, K. J., Clavane, E. M., Trevelyan, C. J., Brown, J., Przemyłska, L., Watt, N. T., Matthews, L. C., & Meakin, P. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094568 · Cited by 13
Effects of dose change on the success of clinical trials
Shan, G., Ritter, A. R., Miller, J., & Bernick, C. B. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100988 · Cited by 13
Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
Chertkow, H. M., Rockwood, K. J., Hogan, D. B., Phillips, N. D., Montero‐Odasso, M., Amanullah, S., Black, S. E., Bocti, C., BORRIE, M. J., Feldman, H., et al. (2021) · Canadian Geriatrics Journal · doi:10.5770/cgj.24.570 · Cited by 12
Theerasri, A., Janpaijit, S., Tencomnao, T., & Prasansuklab, A. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1591 · Cited by 13
Boada, M., KIPROV, D. D., Anaya, F., López, O. L., Núñez, L., Olazarán, J., Lima, J., Grifols, C., Barceló, M., Rohe, R., et al. (2022) · Journal of Clinical Apheresis · doi:10.1002/jca.22026 · Cited by 14
Recent advances in understanding Alzheimer’s Disease: diagnosis and management strategies
Marín, A., & Budson, A. E. (2023) · Faculty Reviews · doi:10.12703/r/12-24 · Cited by 12
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11
Liang, C., Paclibar, C. G., Gonzaga, N. L., Sison, S. A., Bath, H. S., Biju, A. P., & Mukherjee, J. (2024) · Neurology International · doi:10.3390/neurolint16020031 · Cited by 11
Still grasping at straws: donanemab in Alzheimer’s disease
Doggrell, S. A. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1948010 · Cited by 12
Lambracht-Washington, D., Fu, M., Manouchehri, N., Hynan, L. S., Stuve, O., & Rosenberg, R. N. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100066 · Cited by 9
Quantitative EEG for early differential diagnosis of dementia with Lewy bodies
Iannaccone, S., Houdayer, E., Spina, A., Nocera, G., & Alemanno, F. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1150540 · Cited by 10
Aguree, S., Zolnoori, M., Atwood, T. P., & Owora, A. H. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1242853 · Cited by 10
Shao, Y., Todd, K. W., Shutes‐David, A., Millard, S. P., Brown, K., Thomas, A., Chen, K., Wilson, K. F., Zeng, Q. T., & Tsuang, D. W. (2023) · Big Data and Cognitive Computing · doi:10.3390/bdcc7040167 · Cited by 11
Chen, X., Walton, K. L., Brodaty, H., & Chalton, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231222 · Cited by 10
Brain Stimulation in Alzheimer’s Disease Trials
Benussi, A., & Borroni, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230535 · Cited by 10
Carles, A., Freyssin, A., Guehairia, S., Reguero, T., Vignes, M., Hirbec, H., Rubinstenn, G., & Maurice, T. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01648-9 · Cited by 12
Clear‐headed into old age: Resilience and resistance against brain aging—A PET imaging perspective
Hoenig, M. C., & Drzezga, A. E. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15598 · Cited by 9
Triggering Innate Immune Receptors as New Therapies in Alzheimer’s Disease and Multiple Sclerosis
Piec, P.-A., Pons, V., & Rivest, S. (2021) · Cells · doi:10.3390/cells10082164 · Cited by 10
Jönsson, L., Ivkovic, M., Atri, A., Handels, R. L. H., Gustavsson, A., Hahn‐Pedersen, J. H., León, T., Lilja, M., Gundgaard, J., & Rakêt, L. L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01413-y · Cited by 9
Self-citationSandhu, Y. K., Bath, H. S., Shergill, J., Liang, C., Syed, A. U., Ngo, A., Karim, F., Serrano, G. E., Beach, T. G., & Mukherjee, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147890 · Cited by 9
Lasheen, N. N., Allam, S., Elgarawany, A., Aswa, D. W., Mansour, R., & Farouk, Z. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00933-4 · Cited by 12
Abbott, V., Housden, B. E., & Houldsworth, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf092 · Cited by 9
Perus, L., Busto, G. U., Mangin, J., Bars, E. L., & Gabelle, A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1014559 · Cited by 10
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Bisi, A., Feoli, A., Trezza, A., Viejo, L., Formaggio, F., Bartolini, M., Belluti, F., Gobbi, S., Spiga, O., Caprini, M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106152 · Cited by 8
Escolar, G., Páez, A., & Cid, J. (2022) · Plasmatology · doi:10.1177/26348535221131685 · Cited by 10
Nirogi, R. V. S., Grandhi, V. R., Medapati, R. B., Ganuga, N., Abraham, R., Thentu, J. B., Palacharla, V. R. C., Petlu, S., Srirangavaram, M., Subramanian, R., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175625 · Cited by 7
Walter, S., Langford, O., Jimenez‐Maggiora, G. A., Abdel‐Latif, S., Rissman, R. A., Grill, J. D., Karlawish, J. H., Atri, A., Bruschi, S., Hussen, K., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.101 · Cited by 7
Self-citationAo, J., Picard, C., Auld, D. S., Zetterberg, H., Brinkmalm, A., Blennow, K., Villeneuve, S., Breitner, J. C. S., Poirier, J., Breitner, J., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-024-02884-z · Cited by 11
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?
Lanctôt, K. L., Jönsson, L., Atri, A., Paulsen, R., Mattke, S., Hahn‐Pedersen, J. H., Polavieja, P., Maltesen, T., León, T., Gustavsson, A., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70081 · Cited by 7
Self-citationAducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease
Grover, S., & Jain, S. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00944-4 · Cited by 7
Aduhelm: The Best Hope for Alzheimer’s Disease Patients or the Worst Decision the FDA Has Ever Made?
Kurkinen, M., & Tran, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215105 · Cited by 7
Soo, S. A., Kumar, D., Leow, Y. J., Koh, C. L., Saffari, S. E., & Kandiah, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221301 · Cited by 6
Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s
Kozani, P. S., Naseri, A., Kozani, P. S., Khatami, S., & Sheikhi, A. (2021) · Trends in Medical Sciences · doi:10.5812/tms.116686 · Cited by 6
Frederiksen, K. S., Boada, M., Dubois, B., Engelborghs, S., Frisoni, G. B., Georges, J., Hort, J., Jönsson, L., Kramberger, M. G., Ousset, P., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01766-y · Cited by 9
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
Anderson, A., & Malone, M. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.bg21120com4 · Cited by 5
Malik, N., Miah, M.-U., Galgani, A., McAleese, K. E., Walker, L., LeBeau, F. E. N., Attems, J., Outeiro, T. F., Thomas, A. J., & Koss, D. J. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02691-4 · Cited by 5
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
Russ, H., Mazzanti, M., Parsons, C. G., Riemann, K., Gebauer, A., & Rammes, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105794 · Cited by 7
The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment
Dabur, M., Loureiro, J. A., & Pereira, M. D. C. (2022) · Biochimie · doi:10.1016/j.biochi.2022.08.003 · Cited by 6
Aducanumab for Alzheimer's disease: An update
Retinasamy, T., & Shaikh, M. F. (2021) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v4i2.81 · Cited by 5
Emam, N. E., Refaey, R. H., El-Ashrey, M. K., Mahmoud, W. R., Nissan, Y. M., & Seif, E. M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109630 · Cited by 4
The potential of low-field MRI for global dementia care
Evans, T. E., Harper, J. R., Salehi, A., WEBB, A. G., Cole, J. H., Correa, A., Adams, H. H. H., Cash, D. M., & Jones, D. K. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01199-7 · Cited by 4
Gonzaga, N. L., Karim, F., Liang, C., & Mukherjee, J. (2025) · Biomolecules · doi:10.3390/biom15040592 · Cited by 4
Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease
Lee, A. Y. (2021) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2021.3.4 · Cited by 4
Amatya, R., Min, K. A., & Shin, M. C. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00566-y · Cited by 4
Developing systems in yeast to address Alzheimer's disease
Dhakal, S., & Macreadie, I. G. (2022) · Methods in microbiology · doi:10.1016/bs.mim.2022.02.001 · Cited by 4
Mervosh, N. L., Bilici, N., Wısnıewskı, T., & Devi, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251366657 · Cited by 5
Yang, M., & Liang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839620 · Cited by 3
Self Assessment Memory Scale (SAMS), a new simple method for evaluating memory function
Kowa, H., Uchimura, M., Ohashi, A., Hiroe, M., & Ono, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1024497 · Cited by 3
Park, S., Shin, J., Kim, K., Kim, D., Lee, W. S., Lee, J., Cho, I., Park, I. W., Yoon, S., Lee, S., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00006 · Cited by 3
Su, Y., Zeng, X., Zhang, L., Bian, Y., Wang, Y., & Ma, B. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-024-00664-5 · Cited by 3
Padala, S., Setti, S. E., Raymick, J. B., Hanig, J. P., & Sarkar, S. (2024) · Current Alzheimer Research · doi:10.2174/0115672050295561240327055835 · Cited by 3
Ford, J., Kafetsouli, D., Wilson, H., Udeh‐Momoh, C. T., Politis, M., Ahmadi‐Abhari, S., Rabiner, I., & Middleton, L. T. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.7 · Cited by 3
Saunders, S., Sheehan, S., Terrera, G. M., Luz, S. F., & Ritchie, C. W. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00433-2 · Cited by 3
A paradigm of the diagnosis and treatment for the whole process of Alzheimer’s disease
Shi, J., Du, Y., Wang, H., Zhang, N., Chen, W., Ni, J., Lu, X., Sun, Y., Wang, G., Liu, J., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2672193 · Cited by 3
Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
Yang, J., & Bradford, A. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3453 · Cited by 2
Grifols, C., Barceló, M., Núñez, L., Szczepiorkowski, Z. M., Boada, M., López, O. L., & Páez, A. (2023) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14002 · Cited by 2
The impact of Dual-Tasking on mnestic performance in normal agingPreprint
Contemori, G., Iorio, C., & Bonato, M. (2022) · doi:10.31234/osf.io/z86tj · Cited by 2
Yashkin, A. P., Kolpakov, S. A., Ukraintseva, S. V., Yashin, A. I., & Akushevich, I. V. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00170-z · Cited by 1
The impact of dual-tasking on mnestic performance in normal ageing
Contemori, G., Iorio, C., & Bonato, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96784-z · Cited by 2
Goonetilleke, U. K. D. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-0523-1_35 · Cited by 1
Aducanumab: advancing Alzheimer’s treatment through regulation of excessive β-amyloid accumulation
Kachungunu, C. N. K., Mashal, S. N., & Sahu, P. S. (2025) · Academia Immunity and Disease · doi:10.20935/acadimmunodis8055 · Cited by 1
Raj, M. D. A. P., Ma, S., Bhat, R. M., Vaishnav, R., Siyabi, M. Y. A., Maamari, Y. I. A., & Amr, M. (2026) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_317_25 · Cited by 1
Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease
Thibault, E. G., Montenegro, G. A. D. C., Becker, J. A., Price, J. C., Healy, B. C., Hanseeuw, B. J., Buckley, R. F., Jacobs, H. I. L., Properzi, M. J., Sperling, R. A., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100529 · Cited by 1
Cao, K., Xie, J., Liang, X., Li, Y., Gong, H., & Luo, H. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00917 · Cited by 2
Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer’s Disease
Seo, Y., Jang, H., & Lee, H. (2022) · Life · doi:10.3390/life12020275 · Cited by 1
Sasaki, R., Suico, M. A., Chosa, K., Teranishi, Y., Sato, T., Kagami, A., Kotani, S., Kato, H., Hitora, Y., Tsukamoto, S., et al. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.11.004 · Cited by 1
Stationary distribution and extinction of a stochastic Alzheimer's disease model
Lang, R., Tan, Y., & Mu, Y. (2023) · AIMS Mathematics · doi:10.3934/math.20231185 · Cited by 1
Stojanovic, M., Waters, A. B., Kiselica, A. M., & Benge, J. F. (2023) · Applied Neuropsychology Adult · doi:10.1080/23279095.2023.2247109 · Cited by 1
The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice
Gauthier, S. G., & Rosa‐Neto, P. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.44 · Cited by 1
Erstes kausal wirkendes Medikament gegen Alzheimer?
Häger, K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01182-1 · Cited by 1
Medicinal Cannabis for Alzheimer's Disease
Steiner, G. Z., Coles, M., Jaye, K. M., Metri, N., Butt, A. S., Christofides, K., McPartland, J., Al-Modhefer, Z., Karamacoska, D., Russo, E. B., et al. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5652-1.ch001 · Cited by 1
El anticuerpo aducanumab en la enfermedad de Alzheimer
Bombón-Albán, P. E. (2021) · Neurología Argentina · doi:10.1016/j.neuarg.2021.07.002
野崎, 剛., & 須藤, 信. (2013) · 心身医学 · doi:10.15064/jjpm.53.1_20
Exploring the Efficacy of Anti-amyloid-β Therapeutics in Treating Alzheimer Disease
Downey, C. (2022) · Youth STEM Matters · doi:10.51892/ysm.1.202201
Cummings, J. L. (2021) · touchREVIEWS in Neurology · doi:10.17925/usn.2021.17.2.70
Self-citationBannawongsil, T., Yamada, A., Nakamura, A., Uchihara, T., & Yokota, T. (2022) · Histochemistry and Cell Biology · doi:10.1007/s00418-022-02107-y
Park, K. H., Jang, J., Suh, J., Yi, S., Bae, J., Lim, J., Lee, H., Chin, J., Park, Y. H., Hong, Y. J., et al. (2022) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2022.21.2.45
Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
Vorobev, S. V., Emelin, А. Y., Yanishevskij, S. N., Kostina, E. V., & Galaeva, A. A. (2022) · Neurology Bulletin · doi:10.17816/nb108278
Filatov, A., & Grossman, J. T. (2022) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v2-i8-12
Explorando o papel dos RNAs longos não codificadores na doença de Alzheimer
Vasquez, F. J. D. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-08082022-105803
McCall, I. C. (2022) · AJOB Neuroscience · doi:10.1080/21507740.2022.2126552
Nirogi, R. V. S., Benade, V. S., Ramkumar, R., ., S., Jetta, S., Shinde, A. K., Goyal, V., Pandey, S. K., Jayarajan, P., & Jasti, V. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3061
Wısnıewskı, T., & Goñi, F. (2023) · Springer eBooks · doi:10.1007/978-3-031-20565-1_37
Dementia and Older Persons in USA
Mpofu, E., Alagood, J., Li, X., Ntinda, K., & Yin, C. (2023) · Springer eBooks · doi:10.1007/978-3-030-96778-9_114-1
(2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00007-9
Aducanumab - a potential pharmacological therapeutic treatments for Alzheimer’s disease
Ding, C. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6170
Noninfectious Disease Vaccines
Speiser, D. E., El-Turabi, A., & Bachmann, M. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00042-6
Dementia and Older Persons in USA
Mpofu, E., Alagood, J., Li, X., Ntinda, K., & Yin, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25110-8_114
Malik, N., Miah, M.-U., Galgani, A., McAleese, K. E., Walker, L., LeBeau, F. E. N., Attems, J., Outeiro, T. F., Thomas, A. J., & Koss, D. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.559720
Análise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer
Turke, C. C., Neto, V. C., Zumbano, G. M., Shimada, T., Akamine, M. Y. E., Camargo, R. M., Morelli, S. D. A., & Estrela, H. F. G. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-115
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Joodaki, M., Shirazi, M. M., & Hosseini, N. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.3.219
Gregory, S., Saunders, S., & Ritchie, C. W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-822240-9.00016-8
Hosseini, Z., Mohebbi, A., Kiani, I., Taghilou, A., Mohammadjafari, A., & Aghamollaii, V. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70134
Metadata
- Authors
- Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S.
- Affiliations
- University of Nevada, Las Vegas (US)
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Brown University (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's Research & Therapy
- Published
- 2021-05-10
- Volume
- 13
- Issue
- 1
- Pages
- 98-98
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC8111757
- OpenAlex
- W3161140821
- Cited by
- 224
- References
- 19
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 31 · 2023: 52 · 2022: 87 · 2021: 31
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- National Institute on Aging (R01AG053798, P20AG068053, R35AG71476)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- aducanumab, amyloid-beta, Alzheimer's disease, anti-amyloid therapy, clinical benefit
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Amyloid beta-Peptides, Amyloidogenic Proteins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
